Strategic partnership with leading US EEG provider

Highlights:

- Epiminder has entered a 5-year rolling strategic partnership with Stratus Neuro ('Stratus'), a leading provider of EEG and neurodiagnostic solutions in the US, to support Epiminder's commercialisation plans. This new contract extends the existing contract with Stratus that is supporting the DETECT US reimbursement study.
- The Minder® System's continuous, long-term EEG monitoring data will be integrated into the StratusEEG™ platform, giving clinicians a single, familiar workflow to review it.
- Epiminder gains access to a clinically proven, cloud-based EEG platform already trusted and used by over 7,000 US clinicians and administrators that will support the DETECT program and commercial launch of the next generation Minder System.
- Leveraging Stratus' trusted relationships with US epilepsy centres will enable Minder to reach clinicians through a review platform that they already know and use. This will support and assist Minder's commercial adoption.

Melbourne, Australia & Dallas, United States – 17th November 2026 – Epiminder Limited (ASX: EPI), a pioneer medical device company developing breakthrough epilepsy monitoring technology, today announced a strategic partnership with Stratus, whose StratusEEG platform is the most widely used cloud-based EEG review service in the United States. This agreement will support Epiminder's commercialisation plans by providing access to EEG data via a platform that is widely used in the US.

The Minder System is the only system that delivers continuous, bilateral, long-term EEG data for patients with drug-resistant epilepsy, capturing brain activity not just during a clinical visit but across a patient's daily life, 24/7. This partnership puts that data directly into an EEG platform neurologists already rely on, turning continuous monitoring into clinical reality.

The strategic partnership pairs Minder's ability to capture continuous EEG data over months and years with Stratus's proven platform, StratusEEG, for EEG review and interpretation. Clinicians will have efficient access to insights that can change the clinical pathway for patients who haven't received a confirmed diagnosis through conventional monitoring. The Minder System and StratusEEG remain separate products, each retaining its own regulatory clearances and manufacturer of record.

The agreement establishes a multi-year commercial relationship that builds on the current agreement supporting the DETECT study. It includes standard terms for platform access, data services and sharing, termination, cybersecurity, warranties, and confidentiality. Each party retains its own regulatory clearances and Epiminder retains ownership of Minder patient data.

Dr Rohan Hoare, CEO of Epiminder, said, “Bringing Minder together with the StratusEEG platform means our continuous EEG monitoring data is available on the most utilized and trusted EEG viewing platform in the US market. Through a joint R&D program, we can build on the strengths of both organizations and advance a new paradigm for EEG monitoring.”

Charlie Alvarez, CEO of Stratus, said, “Stratus is proud to partner with Epiminder in bringing the first bilateral, implantable continuous EEG monitor to patients across the United States. Together, we can give clinicians a complete view of their patients’ EEG data and help close the gap in care for people living with drug-resistant epilepsy.”

Professor Mark Cook MD, Epiminder’s Founder and Chief Medical Officer, said, “Minder’s clinical value comes from capturing patterns of brain activity that only emerge over weeks, months and years of continuous monitoring. Bringing that data into StratusEEG lets clinicians integrate Minder insights into practice quickly, translating continuous brain activity data into better decisions and outcomes for patients.”

This announcement was approved by the Board of Directors.

ENDS

Investor & Media Enquiries

Gabriella Hold
The Capital Network
P: +61 2 7257 7338
E: gaby@thecapitalnetwork.com.au

Julia Maguire
The Capital Network
P: +61 2 7257 7338
E: julia@thecapitalnetwork.com.au

About Minder®

Minder® is a minimally invasive implantable continuous EEG Monitoring (iCEM®) device that provides clinicians and patients with long-term, objective data on brain electrical activity. The system continuously records bilateral subscalp EEG and transmits data via an external wearable and smartphone application to a secure cloud platform. Patients wear the device during their normal daily activities, enabling real-world monitoring over months or years.

The Minder® System was authorised by the FDA via the de novo pathway and is being used in DETECT as a marketed device in a post-market study. The UMPIRE first-in-human multicentre trial, published in Epilepsia (2025), demonstrated Minder’s safety and high-quality signal acquisition across extended monitoring periods.

About Epiminder

Founded in 2017 by Professor Mark Cook together with the Bionics Institute, St Vincent's Hospital, the University of Melbourne and Cochlear Limited, Epiminder is a medical device and information solutions company focused on developing diagnostic and treatment tools for epilepsy and other seizure disorders where continuous monitoring is required. Epiminder is headquartered in Melbourne, Australia and has offices in the United States.

About Stratus

Stratus is a leading provider of EEG solutions in the United States, offering global EEG technology through its StratusEEG software. Its offerings span remote ICU and EMU monitoring, EEG review software, ambulatory VEEGs, and custom EEG solutions, integrating AI and deep learning to support (not replace) clinicians. Stratus also serves centralized and decentralized clinical trials and biomarker detection, drawing on over 2.2 million hours of anonymized EEG data through its R&D division's database.